Schonfeld Strategic Advisors LLC Aravive, Inc. Transaction History

Schonfeld Strategic Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.61 - $1.03 $61 - $103	-100 Reduced 0.88%	11,300 $10,000
Q4 2021 Feb 14, 2022	SELL	$2.19 - $4.07 $219 - $407	-100 Reduced 0.87%	11,400 $25,000
Q3 2021 Nov 16, 2021	BUY	$3.67 - $5.8 $367 - $580	100 Added 0.88%	11,500 $43,000
Q2 2021 Aug 16, 2021	BUY	$4.65 - $6.42 $930 - $1,284	200 Added 1.79%	11,400 $68,000
Q4 2020 Feb 16, 2021	BUY	$4.36 - $6.51 $48,832 - $72,912	11,200 New	11,200 $64,000
Q1 2020 May 15, 2020	SELL	$3.5 - $13.77 $209,079 - $822,578	-59,737 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$6.21 - $14.02 $370,966 - $837,512	59,737 New	59,737 $816,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.